A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin - Related Studies

A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin

This study has been completed.

Study NCT00001427. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Ovarian Neoplasms

2	More general conditions related to this trial
		Adnexal Diseases
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Neoplasms
		Neoplasms by Site
		Ovarian Diseases
		Urogenital Neoplasms

3	Interventions listed in this trial
		9-aminocamptothecin

4	Additional drug interventions recognized in this trial
		9-amino-20-camptothecin
		Camptothecin

5	More general drug interventions related to this trial
		Antineoplastic Agents
		Antineoplastic Agents, Phytogenic
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		National Cancer Institute (NCI)